Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings

Record Fiscal 2025 Financial Performance: Record net revenues of $107.3 million, adjusted EBITDA of $28.1 million1, net income of $13.1 million, operating cash flow of $20 million and free cash flow of $13.7 million1 for Fiscal 2025.Stronger Balance Sheet and Earnings Quality: First year of positive retained earnings as at August 31, 2025, supported by continued free cash flow generation and lower leverage.Continued Market Share Expansion: National market share rose to 3.81% in Fiscal 2025, up 32% year over ...